Today: 7 February 2026
Subscribe
Browse Category

NYSE:NUVB News 19 November 2025 - 11 December 2025

Nuvation Bio (NUVB) Soars After $18 Price-Target Hike – Is This High‑Growth Cancer Stock Still a Buy in 2025?

Nuvation Bio (NUVB) Soars After $18 Price-Target Hike – Is This High‑Growth Cancer Stock Still a Buy in 2025?

Nuvation Bio Inc. (NYSE: NUVB) has quietly morphed from an obscure penny stock into one of 2025’s wildest oncology stories. As of December 11, 2025, the stock is trading in the high single digits (around $7.8–$8.0), up roughly 200% year‑to‑date, following a string of clinical wins, a first drug approval, and a wave of fresh analyst upgrades. TipRanks+1 The latest jolt came today, when H.C. Wainwright raised its 12‑month price target on NUVB from $10 to $18 while reiterating a Buy / Strong Buy rating – implying well over 100% upside from recent levels. Investing.com+1 Here’s a deep dive into
11 December 2025
·····
Nuvation Bio (NUVB) Stock Soars ~50% Today as B. Riley Starts Coverage With $12 Target – 19 November 2025

Nuvation Bio (NUVB) Stock Soars ~50% Today as B. Riley Starts Coverage With $12 Target – 19 November 2025

NEW YORK, November 19, 2025 – Shares of Nuvation Bio Inc. (NYSE: NUVB) exploded higher on Wednesday after B. Riley Securities initiated coverage with a bullish rating and a $12 price target, adding fresh fuel to a rally driven by the successful launch of the company’s lung cancer drug IBTROZI™ (taletrectinib) and a blockbuster third quarter. Investing.com+2Parameter+2 As of early afternoon on November 19, 2025, NUVB was trading around $7.1–$7.2, up roughly 50% on the day from Tuesday’s close near $4.80, on extremely heavy volume. The stock’s 52‑week range has expanded from about $1.54 at the low to over $7.3
19 November 2025
····

Stock Market Today

Glencore share price steadies after Rio Tinto walks away — what to watch next week

Glencore share price steadies after Rio Tinto walks away — what to watch next week

7 February 2026
Glencore shares closed up 0.6% at 478.1 pence Friday, rebounding after a 7% drop following the collapse of merger talks with Rio Tinto. The company is expected to announce the sale of its Kazzinc stake soon and has signed a non-binding agreement with Orion for a potential $9 billion deal in the DRC. Investors await Glencore’s full-year results on Feb. 18 for further guidance.
RELX share price slides again as AI fears linger, results next week in focus

RELX share price slides again as AI fears linger, results next week in focus

7 February 2026
RELX closed down 4.6% at 2,145 pence in London on Friday, capping a volatile week ahead of its Feb. 12 full-year results. The company bought back 465,361 shares even as selling continued amid investor concerns over AI risks and pricing power. Peers Wolters Kluwer and Thomson Reuters also faced pressure. Markets await RELX’s outlook for 2026 trading.
Go toTop